IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia

Journal of Geriatric Psychiatry and Neurology

Volumn 19, Issue 2, 2006, Pages 114-117

  Rentzos, M ^a   Zoga, M ^a   Paraskevas, G P ^a   Kapaki, E ^a   Rombos, A ^a   Nikolaou, C ^a   Tsoutsou, A ^a   Vassilopoulos, D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Alzheimer's disease; Frontotemporal dementia; Inflammatory mechanisms; Interleukin 15

Indexed keywords

INTERLEUKIN 15;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; FRONTOTEMPORAL DEMENTIA; GLIA CELL; HUMAN; INFLAMMATION; MACROPHAGE; MALE; MONOCYTE; ONSET AGE; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEMENTIA; FEMALE; HUMANS; INTERLEUKIN-15; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 33646584170     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988706286226     Document Type: Article

References (32)

1. Jonuleit H, Wiedemann K, Muller G, et al. Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells. J Immunol 1997; 160:2610-2615.
2. Lee YB, Satoh J, Walker DG, Kim SU. Interleukin-15 gene expression in human astrocytes and microglia in culture. Neuroreport 1996; 7:1062-1066.
3. Doherty TM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol 1996; 156:735-741.
4. Grabstein KH, Eisenmann J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264:965-968.
5. Carson WE, Giri JG, Lindemann MJ, et al. IL-15 is a novel cytokine that activates human NK cells via components of IL-2 receptor. J Exp Med 1994; 180:1395-1405.
6. Verbeek MM, Otte-Holler I, Westphal JR, et al. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol 1991; 144:104-116.
7. Hussain L, Powell D, Howlett D, et al. Identification of a novel aspartic protease (Asp2) as [beta]-secretase. Mol Cell Neurosci 1999; 14:419-427.
8. Akiyama H, Arai T, Kondo H, et al. Cell mediators of inflammation in the Alzheimer disease brain. Alz Dis Assoc Disord 2000; 14(1 suppl):S47-S53.
9. Yong BL, Atsushi N, Seung UK. Cytokines, chemokines and cytokine receptors in human microglia. J Neurosci Res 2002; 69:94-103.
10. McGeer PL, Kawamata T, Walker DG, et al. Microglia in degenerative neurological disease. Glia 1993; 7:84-92.
11. Shoji M, Hirai S, Yamaguchi H, et al. Alpha 1-antichymotrypsin is present in diffuse senile plaques. Am J Pathol 1991; 138:247-257.
12. Strauss S, Bauer J, Ganter U, et al. Detection of interleukin-6 and a-2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer disease patients. Lab Invest 1992; 66:223-230.
13. Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated "acute phase response" in the brain? Immunol Today 1991; 12:217-219.
14. Schnabel J. New Alzheimer's therapy suggested. Science 1993; 260:1719-1720.
15. Rentzos M, Michalopoulou M, Nikolaou C, et al. The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J Neurol Sci 2005; 228:129-135.
16. Rentzos M, Michalopoulou M, Nikolaou C, et al. Serum levels of soluble intercellular adhesion molecule-1 and soluble endothelial leukocyte adhesion molecule-1 in Alzheimer's disease. J Geriatr Psych Neurol 2004; 94:183-189.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984; 34:939-944.
18. Roman GC, Tatemichi TK, Erkinjunti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250-260.
19. Hachinski VC, Iliff LD, Zilh E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32:632-637.
20. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998; 51:1546-1554.
21. Brooks BR. El Escorial World Federation of Neurology, Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Subcommittee on Motor Neuron Disease/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Disease and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994; 124:96-107.
22. Larsen JP, Dupont E. Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994; 89: 242-251.
23. Gomez-Tortosa E, Gonzalo I, Fanjul S, et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer's disease. Arch Neurol 2003; 60:1218-1222.
24. Enghelboreghs S, De Brabander M, De Crée J, et al. Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem Int 1999; 34:523-530.
25. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327:128.
26. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345:1515-1521.
27. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47:425-432.
28. Sjogren M. The pathophysiology of frontotemporal dementia-cytoskeleton abnormalities and autoimmunity? Brain Aging 2002; 2:18-26.
29. Sjogren M, Rosengren L, Minthon L, et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000; 54:1960-1964.
30. Sjogren M, Vallin A. Pathophysiological aspects of frontotemporal dementia - emphasis on cytoskeleton proteins and autoimmunity. Mech Ageing Dev 2001; 122:1923-1925.
31. Marcinkowski T. The diseases of Alzheimer and Pick from the view point of prevention. Med Hypotheses 1996; 46:180-182.
32. Sjogren M, Folkesson S, Blennow K, Tarkowski E. Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry 2004; 75:1107-1111.